Regulacje i polityka gospodarcza · 25/11/2013

National Institutes of Health to Grant Exclusive Patent License to Scion Cardio-vascular for Chitosan/IL-12 Conjugate Immunotherapeutic Products

The National Institutes of Health is issuing a notice under 35 U.S.C. 209 and 37 CFR Part 404, stating its intention to grant an exclusive patent license to Scion Cardio-vascular, a company based in Miami, FL, USA, for the development of immunotherapeutic products using a chitosan/IL-12 conjugate, as described in U.S. Patents and Patent Applications.